ES8707210A1 - Un procedimiento para la produccion de un compuesto de tiazolidindiona hipoglicemico - Google Patents

Un procedimiento para la produccion de un compuesto de tiazolidindiona hipoglicemico

Info

Publication number
ES8707210A1
ES8707210A1 ES555147A ES555147A ES8707210A1 ES 8707210 A1 ES8707210 A1 ES 8707210A1 ES 555147 A ES555147 A ES 555147A ES 555147 A ES555147 A ES 555147A ES 8707210 A1 ES8707210 A1 ES 8707210A1
Authority
ES
Spain
Prior art keywords
benzo
hypoglycemic
dihydro
hypoglycemic thiazolidinediones
thiazolidinediones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES555147A
Other languages
English (en)
Other versions
ES555147A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of ES8707210A1 publication Critical patent/ES8707210A1/es
Publication of ES555147A0 publication Critical patent/ES555147A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Detergent Compositions (AREA)
  • Soil Working Implements (AREA)
  • Saccharide Compounds (AREA)

Abstract

PROCEDIMIENTO PARA PRODUCIR UN COMPUESTO DE TIAZOLIDINDIONA HIPOGLICEMICO. COMPRENDE: A) HACER REACCIONAR ENTRE SI A COMPUESTOS DE FORMULA (II) Y (III), EN PRESENCIA DE ACETATO SODICO, ENTRE 100 Y 250JC, PARA FORMAR UN COMPUESTO DE FORMULA (IV); Y B) REDUCIR A (IV) CON HIDROGENO, EN PRESENCIA DE PD, EN PRESENCIA DE ACETATO SODICO Y ENTRE 140JC Y 200JC, PARA OBTENER UN COMPUESTO DE FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. SIENDO: R, H, CH3 Y OTROS; R1, H, CICLOALQUILO DE C 5 A 7; R2, H O CH3; R4, H, ALQUILO DE C 1 A 6; X, 0,5 Y OTROS; Y N, DE 0 A 2.
ES555147A 1985-05-21 1986-05-20 Un procedimiento para la produccion de un compuesto de tiazolidindiona hipoglicemico Expired ES8707210A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1985/000962 WO1986007056A1 (en) 1985-05-21 1985-05-21 Hypoglycemic thiazolidinediones

Publications (2)

Publication Number Publication Date
ES8707210A1 true ES8707210A1 (es) 1987-07-16
ES555147A0 ES555147A0 (es) 1987-07-16

Family

ID=22188690

Family Applications (1)

Application Number Title Priority Date Filing Date
ES555147A Expired ES8707210A1 (es) 1985-05-21 1986-05-20 Un procedimiento para la produccion de un compuesto de tiazolidindiona hipoglicemico

Country Status (26)

Country Link
US (1) US4703052A (es)
EP (1) EP0207605B1 (es)
JP (1) JPS61271287A (es)
KR (1) KR870000903B1 (es)
CN (1) CN1007248B (es)
AT (1) ATE50256T1 (es)
AU (2) AU560179B2 (es)
CA (1) CA1279320C (es)
DD (1) DD261154A5 (es)
DE (1) DE3668892D1 (es)
DK (1) DK233586A (es)
EG (1) EG18043A (es)
ES (1) ES8707210A1 (es)
FI (1) FI89268C (es)
GR (1) GR861297B (es)
HU (1) HU210339B (es)
IE (1) IE58674B1 (es)
IL (1) IL78831A (es)
MY (1) MY108496A (es)
NO (1) NO166448C (es)
PH (2) PH22313A (es)
PL (1) PL147479B1 (es)
PT (1) PT82610B (es)
WO (1) WO1986007056A1 (es)
YU (1) YU44573B (es)
ZA (1) ZA863762B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
GB8713861D0 (en) * 1987-06-13 1987-07-15 Beecham Group Plc Compounds
US4897406A (en) * 1987-11-13 1990-01-30 Nisshin Flour Milling Co., Ltd. Rhodanine derivatives and pharmaceutical compositions
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008652A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5130379A (en) * 1988-03-08 1992-07-14 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5036079A (en) * 1989-12-07 1991-07-30 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5089637A (en) * 1990-03-21 1992-02-18 Pfizer Inc. Process and intermediates for 2r-benzyl-chroman-6-carbaldehyde
EP0454501B1 (en) * 1990-04-27 2001-09-05 Sankyo Company Limited Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
KR930701420A (ko) * 1990-08-23 1993-06-11 알렌 제이. 스피겔 혈당저하제로서의 하이드록시우레아 유도체
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
TW222626B (es) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE4142190A1 (de) * 1991-12-20 1993-06-24 Bayer Ag Verfahren zur herstellung von optisch aktiven (alpha)-hydroxycarbonsaeuren
FR2688220A1 (fr) * 1992-03-06 1993-09-10 Adir Nouveaux derives de thiazolidine-2,4-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5498621A (en) * 1992-05-01 1996-03-12 Pfizer Inc. Oxazolidinedione hypoglycemic agents
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JP3195455B2 (ja) * 1993-01-06 2001-08-06 ウェルファイド株式会社 キノリン−３−酢酸誘導体、その製造法と用途
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5401761A (en) * 1993-12-09 1995-03-28 Pfizer, Inc. Thiazolidinedione hypoglycemic agents
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
GB9604340D0 (en) * 1996-02-29 1996-05-01 Unilever Plc Antiperspirant aerosol composition and method of making same
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
AU708919B2 (en) * 1996-04-04 1999-08-19 Sankyo Company Limited Phenylalkylcarboxylic acid derivatives
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
ID24376A (id) 1997-10-02 2000-07-13 Sankyo Co Turunan-turunan asam amidokarboksilat
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
AU1507799A (en) * 1997-12-16 1999-07-05 Sankyo Company Limited Leukemia remedy
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
CA2350599A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
AU6315300A (en) * 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
ES2433476T3 (es) 2000-01-21 2013-12-11 Novartis Ag Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
US6958355B2 (en) * 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2001294673A1 (en) * 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
KR100711757B1 (ko) * 2000-12-22 2007-04-25 재단법인 포항산업과학연구원 폐수처리용 활성화 슬래그 및 이를 이용한 폐수처리방법
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
CA2489779A1 (en) * 2002-07-10 2004-01-22 Applied Research Systems Ars Holding N.V. Use of compounds for increasing spermatozoa motility
BR0312752A (pt) * 2002-07-10 2005-04-26 Applied Research Systems Derivados de benzeno fundido de azolidinona-vinil
US8637503B2 (en) * 2003-05-16 2014-01-28 Board Of Regents, The University Of Texas System Phenothiazine enantiomers as agents for the prevention of bone loss
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2014068397A1 (en) 2012-11-05 2014-05-08 Commissariat A L'energie Atomique Et Aux Energies Atlternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
CN116535379B (zh) * 2023-06-29 2023-09-19 希格生科（深圳）有限公司 化合物及其医药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
US4342771A (en) 1981-01-02 1982-08-03 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
ATE45574T1 (de) 1983-01-17 1989-09-15 Pfizer Aldosereduktasehemmende 5-(2alkoxyphenyl)thiazolidinedione.
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi

Also Published As

Publication number Publication date
AU7507487A (en) 1987-10-15
IL78831A0 (en) 1986-09-30
PT82610A (en) 1986-06-01
JPH0586953B2 (es) 1993-12-14
EP0207605A1 (en) 1987-01-07
PH22313A (en) 1988-07-29
JPS61271287A (ja) 1986-12-01
DK233586D0 (da) 1986-05-20
ZA863762B (en) 1988-05-25
US4703052A (en) 1987-10-27
IE58674B1 (en) 1993-11-03
EG18043A (en) 1992-11-30
FI89268B (fi) 1993-05-31
NO166448C (no) 1991-07-24
AU5758086A (en) 1987-01-08
AU560179B2 (en) 1987-04-02
FI870219A0 (fi) 1987-01-20
YU44573B (en) 1990-10-31
MY108496A (en) 1996-10-31
AU583991B2 (en) 1989-05-11
YU83786A (en) 1987-12-31
ES555147A0 (es) 1987-07-16
NO870241D0 (no) 1987-01-20
PH25226A (en) 1991-03-27
KR870000903B1 (ko) 1987-05-04
PL147479B1 (en) 1989-06-30
CN86104075A (zh) 1987-03-11
FI870219A (fi) 1987-01-20
WO1986007056A1 (en) 1986-12-04
ATE50256T1 (de) 1990-02-15
NO166448B (no) 1991-04-15
IE861336L (en) 1986-11-21
HU210339B (en) 1995-03-28
EP0207605B1 (en) 1990-02-07
FI89268C (fi) 1993-09-10
IL78831A (en) 1990-11-29
PT82610B (pt) 1988-11-30
DK233586A (da) 1986-11-22
GR861297B (en) 1986-09-16
CA1279320C (en) 1991-01-22
NO870241L (no) 1987-03-20
HUT45247A (en) 1988-06-28
DD261154A5 (de) 1988-10-19
CN1007248B (zh) 1990-03-21
DE3668892D1 (en) 1990-03-15
KR860009010A (ko) 1986-12-19

Similar Documents

Publication Publication Date Title
ES8707210A1 (es) Un procedimiento para la produccion de un compuesto de tiazolidindiona hipoglicemico
PL262105A1 (en) The method of manufacture of new derivatives of benzimidazole
ES8802228A1 (es) Un procedimiento para la preparacion de nuevas piranopiridinas
AU4536389A (en) Anti-antherosclerotic diaryl compounds
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
EP0272704A3 (en) Use of pyrazole derivatives in the treatment of immunity diseases and nephropathy
HUT46214A (en) Process for producing medical preparation suitable for treatment of peptic ulcer
GB8608893D0 (en) D-nor-7-ergoline derivatives
EP0784973A3 (en) Quinoxaline derivatives for treating tinnitus
JPS57140783A (en) 1-benzyl-4-(4-(2-pyrimidinylamino)benzyl)-2, 3-dioxopiperazine derivative and its salt, their preparation, and carcinostatic agent containing the same
HK34095A (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20040519